Biogen (BIIB) reported Q4 non-GAAP earnings Friday of $1.99 per diluted share, down from $3.44 a year earlier.

Analysts polled by FactSet expected $1.63.

Revenue for the quarter ended Dec. 31 was $2.28 billion, down from $2.46 billion a year earlier.

Analysts surveyed by FactSet expected $2.20 billion.

For 2026, the company expects non-GAAP EPS of $15.25 to $16.25 and revenue decline by a mid-single digit percentage from a year earlier.

Analysts polled by FactSet expect non-GAAP EPS of $14.93.

Biogen shares were up 1.3% in recent premarket activity.